报价延迟最少15分钟:2025/09/14 16:50 EDT
常规时段
|
|
|
|
|
||||||||||||
|
|
|
|
|
2.95 
|
|
|
| 价值评估 |
|
盈利(现时/预测)
-0.18/0.11
|
|
企业价值
835.02M
|
| 资产负债 |
|
每股账面净值
0.11
|
| 现金流量 |
|
现金流量率
--
|
| 损益表 |
|
收益
160.18M
|
|
每股收益
0.76
|
|
同行比较
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
报价延迟最少15分钟：2025/09/14 16:50 EDT
同行比较之报价最少15分钟延迟
|
业务概览
|
|||
| Akebia Therapeutics Inc is a fully integrated biopharmaceutical company. The Company's operating segment is the business of developing and commercializing novel therapeutics for people with kidney disease. The current portfolio of the company includes Auryxia (ferric citrate), a medicine approved and marketed in the United States for the control of serum phosphorus levels in adult patients with dialysis-dependent chronic kidney disease and the treatment of iron deficiency anemia, in adult patients with non-dialysis-dependent chronic kidney disease, Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, inhibitor approved in Japan for the treatment of anemia due to chronic kidney disease, in adult patients, HIF-PH inhibitors in preclinical development. |
